Skip to main content
. Author manuscript; available in PMC: 2011 Aug 4.
Published in final edited form as: Mem Inst Oswaldo Cruz. 2010 Aug;105(5):687–691. doi: 10.1590/s0074-02762010000500015

Figure 3. Mucosal protective immunity induced by intranasal CpG-gp82 immunization.

Figure 3

BALB/c mice were immunized intranasally twice two weeks apart with 10μg CpG 1826 mixed with 10 μg gp82 or control GST protein. Four weeks after the final immunization, groups of mice were challenged with 5,000 BFT s.c. (a) or with 1,000 IMT PO (b). Control and CpG-gp82 immunized mice failed to survive challenge with a normally lethal dose of T. cruzi BFT (panel a). However, as compared with the control immunized group, mice vaccinated with CpG-gp82 had significantly lower amounts of T. cruzi DNA detectable in gastric DNA samples taken 12 days post infection as determined by T. cruzi specific real-time PCR (panel b, p < 0.05 using Mann-Whitney U test).